{{Drugbox
| verifiedrevid =
| IUPAC_name = 4-[(1''R'',3''S'')-6-chloro-3-phenyl-2,3-dihydro-1''H''-inden-1-yl]-1,2,2-trimethylpiperazine
| image = Zicronapine.svg
| width = 200px

<!--Clinical data-->
| tradename =  
| Drugs.com =
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- Unscheduled / S2 / S4 / S8 -->
| legal_UK = <!-- GSL / P / POM / CD -->
| legal_US = <!-- OTC / Rx-only -->
| legal_status =
| routes_of_administration = 
 
<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =
| excretion =  
<!--Identifiers-->
| CAS_number = 170381-16-5
| ATC_prefix =
| ATC_suffix =
| ATC_supplemental =  
| PubChem = 11465618
| DrugBank = DB05828
| ChemSpiderID = 9640456
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = QZV11V7G6A
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D10329
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL =

<!--Chemical data-->
| C=22 | H=27 | N=2 | Cl=1
| molecular_weight = 354.9 g/mol
| smiles = Clc1ccc4c(c1)[C@H](N2CC(N(C)CC2)(C)C)C[C@H]4c3ccccc3
| StdInChI = 1S/C22H27ClN2/c1-22(2)15-25(12-11-24(22)3)21-14-19(16-7-5-4-6-8-16)18-10-9-17(23)13-20(18)21/h4-10,13,19,21H,11-12,14-15H2,1-3H3/t19-,21+/m0/s1
| StdInChIKey = BYPMJBXPNZMNQD-PZJWPPBQSA-N
}}

'''Zicronapine''' ({{IPAc-en|z|aɪ|ˈ|k|r|ɒ|n|ə|p|iː|n}} {{respell|zye|KRON|ə-peen}}, previously known as '''Lu 31-130''') is an [[atypical antipsychotic]] medication formerly under development by [[Lundbeck|H. Lundbeck A/S]]. In [[Phases_of_clinical_research#Phase_II|phase II studies]] zicronapine showed statistically significant separation from placebo and convincing efficacy and safety data when compared to [[olanzapine]].<ref>{{cite web|title=The clinical phase III programme commenced on zicronapine|url=http://investor.lundbeck.com/releasedetail.cfm?ReleaseID=608573|accessdate=6 February 2014|date=January 20, 2011}}</ref> 

Zicronapine exhibits monoaminergic activity and has a multi-receptorial profile. ''In vitro'' and ''in vivo'' it has shown potent antagonistic effects at dopamine [[Dopamine receptor D1|D<sub>1</sub>]], [[Dopamine receptor D2|D<sub>2</sub>]] and serotonin [[5-HT2A receptor|5HT<sub>2A</sub>]] receptors.<ref>{{cite web|title=Zicronapine shows significant positive data in clinical phase II in the treatment of patients with schizophrenia - planning for continued clinical work|url=http://investor.lundbeck.com/releasedetail.cfm?ReleaseID=608605|accessdate=6 February 2014|date=December 18, 2009}}</ref>

In 2014 Lundbeck removed zicronapine from its development portfolio in favor of pursuing the more promising antipsychotic [[Lu AF35700]] (a [[prodrug]] of [[Lu AF356152]]).<ref>{{cite web|title=Performance in 2014 positions Lundbeck well for 2015 and beyond|url=http://www.euroinvestor.dk/pdf/cse/2015/02/13101242/Lundbeck%20FY2014%20Results.pdf|accessdate=18 June 2015|date=February 5, 2015}}</ref>

==References==
{{reflist}}

{{Antipsychotics}}
{{Dopaminergics}}
{{Serotonergics}}

[[Category:Abandoned drugs]]
[[Category:Atypical antipsychotics]]
[[Category:Chloroarenes]]
[[Category:Indanes]]
[[Category:Piperazines]]

{{pharma-stub}}
{{Psychiatry-stub}}